The fairly low incidence of adverse events related to genital infections and the absence of significant difference from the control group were consistent with the results of previous studies investigating tofogliflozin as a study drug in Japanese patients with T2DM [11, 12], although genital infections have been commonly known as an adverse event related to SGLT2 inhibitor treatment and thus should be administered with caution. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.